These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 31387107)

  • 21. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies.
    Cosme A; Torrente Iranzo S; Montes Ros M; Fernández-Reyes Silvestre M; Alonso Galán H; Lizasoain J; Bujanda L
    Helicobacter; 2019 Feb; 24(1):e12557. PubMed ID: 30460730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan.
    Yamade M; Sugimoto M; Uotani T; Nishino M; Kodaira C; Furuta T
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1457-61. PubMed ID: 21679250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
    Zullo A; Fiorini G; Scaccianoce G; Portincasa P; De Francesco V; Vassallo R; Urban F; Monica F; Mogavero G; Amato A; Vaira D
    J Gastrointestin Liver Dis; 2019 Mar; 28(1):11-14. PubMed ID: 30851166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.
    Miehlke S; Krasz S; Schneider-Brachert W; Kuhlisch E; Berning M; Madisch A; Laass MW; Neumeyer M; Jebens C; Zekorn C; Knoth H; Vieth M; Stolte M; Lehn N; Morgner A
    Helicobacter; 2011 Dec; 16(6):420-6. PubMed ID: 22059392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on quinolone-containing rescue therapies for
    Mori H; Suzuki H
    World J Gastroenterol; 2020 Apr; 26(15):1733-1744. PubMed ID: 32351290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment.
    Luo L; Ji Y; Yu L; Huang Y; Liang X; Graham DY; Lu H
    Dig Dis Sci; 2020 Dec; 65(12):3639-3646. PubMed ID: 32020360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
    World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
    Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
    Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
    Adachi T; Matsui S; Watanabe T; Okamoto K; Okamoto A; Kono M; Yamada M; Nagai T; Komeda Y; Minaga K; Kamata K; Yamao K; Takenaka M; Asakuma Y; Sakurai T; Nishida N; Kashida H; Kudo M
    Oncology; 2017; 93 Suppl 1():15-19. PubMed ID: 29258111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.
    Murakami K; Furuta T; Ando T; Nakajima T; Inui Y; Oshima T; Tomita T; Mabe K; Sasaki M; Suganuma T; Nomura H; Satoh K; Hori S; Inoue S; Tomokane T; Kudo M; Inaba T; Take S; Ohkusa T; Yamamoto S; Mizuno S; Kamoshida T; Amagai K; Iwamoto J; Miwa J; Kodama M; Okimoto T; Kato M; Asaka M;
    J Gastroenterol; 2013 Oct; 48(10):1128-35. PubMed ID: 23307042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori.
    Lim HC; Lee YJ; An B; Lee SW; Lee YC; Moon BS
    Helicobacter; 2014 Dec; 19(6):455-61. PubMed ID: 25231089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzales B; Zampeli E; Grivas E; Spiliadi C; Sotiropoulou M; Petraki K; Zografos K; Laoudi F; Sgouras D; Mentis A; Kasapidis P; Michopoulos S
    Eur J Intern Med; 2016 Jul; 32():84-90. PubMed ID: 27134145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.
    Nishizawa T; Suzuki H; Maekawa T; Harada N; Toyokawa T; Kuwai T; Ohara M; Suzuki T; Kawanishi M; Noguchi K; Yoshio T; Katsushima S; Tsuruta H; Masuda E; Tanaka M; Katayama S; Kawamura N; Nishizawa Y; Hibi T; Takahashi M
    World J Gastroenterol; 2012 Jun; 18(21):2735-8. PubMed ID: 22690086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.
    Sugimoto M; Sahara S; Ichikawa H; Kagami T; Uotani T; Furuta T
    Aliment Pharmacol Ther; 2015 Aug; 42(4):477-83. PubMed ID: 26075959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence of Helicobacter pylori heterogeneity in human stomachs by susceptibility testing and characterization of mutations in drug-resistant isolates.
    Islam JM; Yano Y; Okamoto A; Matsuda R; Shiraishi M; Hashimoto Y; Morita N; Takeuchi H; Suganuma N; Takeuchi H
    Sci Rep; 2024 May; 14(1):12066. PubMed ID: 38802465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection.
    Mestrovic A; Perkovic N; Bozic J; Pavicic Ivelja M; Vukovic J; Kardum G; Puljiz Z; Tonkic A
    PLoS One; 2020; 15(12):e0244500. PubMed ID: 33378403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication: A pilot empirical second-line rescue therapy.
    Mahmoudi L; Farshad S; Seddigh M; Mahmoudi P; Ejtehadi F; Niknam R
    Medicine (Baltimore); 2016 Oct; 95(42):e4410. PubMed ID: 27759625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.